



# Distinct regions in the C-Terminus required for GLP-1R cell surface expression, activity and internalisation



Aiysha Thompson, Venkateswarlu Kanamarlapudi\*

Institute of Life Science 1, College of Medicine, Swansea University, Singleton Park, Swansea SA2 8PP, UK

## ARTICLE INFO

### Article history:

Received 15 December 2014

Received in revised form

7 May 2015

Accepted 10 June 2015

Available online 24 June 2015

### Keywords:

Glucagon like peptide-1 (GLP-1)

GLP-1 receptor (GLP-1R)

G protein coupled receptor (GPCR)

Biosynthetic trafficking

C-terminus

Diabetes

## ABSTRACT

The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), an important drug target in the treatment of type 2 diabetes, is a G-protein coupled receptor (GPCR) that mediates insulin secretion by GLP-1. The N-terminus controls GLP-1R biosynthetic trafficking to the cell surface but the C-terminus involvement in that trafficking is unknown. The aim of this study was to identify distinct regions within the C-terminal domain required for human GLP-1R (hGLP-1R) cell surface expression, activity and internalisation using a number of C-terminal deletions and site-directed mutations. The results of this study revealed that the residues 411–418 within the C-terminal domain of the hGLP-1R are critical in targeting the newly synthesised receptor to the plasma membrane. The residues 419–430 are important for cAMP producing activity of the receptor, most likely by coupling to  $G_{\alpha_s}$ . However, the residues 431–450 within the C-terminus are essential for agonist-induced hGLP-1R internalisation. In conclusion, these findings demonstrate the hGLP-1R has distinct regions within the C-terminal domain required for its cell surface expression, activity and agonist-induced internalisation.

© 2015 Elsevier Ireland Ltd. All rights reserved.

## 1. Introduction

Glucagon like peptide-1 (GLP-1) mediates insulin secretion by acting on the GLP-1 receptor (GLP-1R), making the receptor an

important target and of high therapeutic potential in the treatment of type 2 diabetes (Gallwitz, 2010; Thompson and Kanamarlapudi, 2013). GLP-1 in vivo half-life is very short (~1.5 min) due to its rapid proteolytic degradation by dipeptidyl peptidase-IV (DPP-IV) and therefore long acting GLP-1 analogues such as liraglutide, which have resistance to DPP-IV proteolysis, are developed for the treatment (Meier, 2012). The GLP-1R, which is a member of the family B G-protein coupled receptors (GPCRs), functions at the cell surface by coupling to  $G_{\alpha_s}$  and  $G_{\alpha_q}$  pathways and causing extracellular signal-regulated kinase (ERK) phosphorylation (Thompson and Kanamarlapudi, 2013; Montrose-Rafizadeh et al., 1999). Agonist-induced GLP-1R internalisation plays an important role in glucose induced insulin secretion (Kuna et al., 2013). The GLP-1R internalises with similar kinetics in response to GLP-1 and liraglutide stimulation (Roed et al., 2014). However, the rate of GLP-1R recycling in cells treated with liraglutide is slower than that in cells treated with GLP-1 (Roed et al., 2014). Inhibition of the  $G_{\alpha_q}$  pathway, but not the  $G_{\alpha_s}$  pathway, has recently been shown to significantly reduce agonist-induced GLP-1R internalisation (Thompson and Kanamarlapudi, 2015). In the same study, chemical inhibitors of the  $G_{\alpha_q}$  pathway also shown to suppress GLP-1-induced ERK phosphorylation, indicating that ERK phosphorylation acts downstream of the  $G_{\alpha_q}$  pathway in GLP-1R internalisation (Thompson and Kanamarlapudi, 2015).

**Abbreviations:** 5-HT<sub>2A</sub>, 5-hydroxytryptamine receptor 2a; aa, amino acid; AC, adenylyl cyclase; AR, adrenoceptor; ARF1, ADP-ribosylation factor 1; AT<sub>2</sub>R, angiotensin II receptor; BSA, bovine serum albumin; Ca<sup>2+</sup>, calcium; CaCl<sub>2</sub>, calcium chloride; cAMP, cyclic adenosine monophosphate; D1R, dopamine D1 receptor; DABCO, 1,4-diazabicyclo[2.2.2]octane; DAPI, 4',6-diamidino-2-phenylindole dihydrochloride; DMEM, dulbecco's modified eagle medium; DTT, dithiothreitol; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; FL, full length; FSM, full serum medium; GFP, green fluorescent protein; GLP-1, glucagon like peptide-1; GLP-1R, GLP-1 receptor; GPCR, G-protein coupled receptors; GRK, GPCR kinase; HCl, hydrochloric acid; HEK293, human embryonic kidney 293; hGLP-1R, human GLP-1R; HRP, horseradish peroxidase; IgG, immunoglobulin G; LL, dileucine; M<sub>2</sub>R, M<sub>2</sub> muscarinic receptor; MGC, mammalian gene collection; MgCl<sub>2</sub>, magnesium chloride; mGluR, metabotropic glutamate receptor; NP40, nonidet P40; NaCl, sodium chloride; PBS, phosphate buffered saline; PCR, polymerase chain reaction; PFA, paraformaldehyde; PLC, phospholipase C; PLD, phospholipase D; PMSF, phenylmethanesulfonyl fluoride; PVDF, polyvinylidene fluoride; SDS, sodium dodecyl sulphate; SFM, serum free medium; TBS, tris buffered saline; TBS-T, TBS-0.1% tween 20; TM, transmembrane; VSVG, vesicular stomatitis virus glycoprotein; WT, wild type.

\* Corresponding author.

E-mail address: [k.venkateswarlu@swansea.ac.uk](mailto:k.venkateswarlu@swansea.ac.uk) (V. Kanamarlapudi).

The extracellular N-terminal domain in many GPCRs is important for their biosynthetic trafficking and maturation (Thompson and Kanamarlapudi, 2013; Dong et al., 2007). Like other family B GPCRs, the GLP-1R contains an N-terminal signal peptide (SP) and undergoes N-linked glycosylation, which are important for the newly synthesised receptor cell surface expression (Huang et al., 2010; Chen et al., 2010; Whitaker et al., 2012). We have recently demonstrated the importance of SP cleavage, N-linked glycosylation and the hydrophobic region after the SP (HRASP) within the N-terminus of the GLP-1R for its biosynthetic trafficking to the plasma membrane (Thompson and Kanamarlapudi, 2014). The intracellular C-terminal domain of GPCRs plays a critical role in agonist-induced internalisation, desensitisation, down regulation and arrestin signalling of the receptors (Thompson et al., 2008). Furthermore, the C-terminal region is required for some GPCRs trafficking from the endoplasmic reticulum (ER) to the plasma membrane (Dong et al., 2007). The C-terminal domain of GPCRs is also known to interact with several intracellular proteins involved in the internalisation of the receptor to intracellular signalling pathways (Thompson and Kanamarlapudi, 2013; Dong et al., 2007).

The motifs such as E(X)<sub>3</sub>LL, FN(X)<sub>2</sub>LL(X)<sub>3</sub>L, F(X)<sub>3</sub>F(X)<sub>3</sub>F, YXXΦ and PPXXFR found within the C-terminus of some GPCRs have been shown to be required for newly synthesised GPCR targeting to the plasma membrane (Dong et al., 2007). Some GPCRs possess a helix-8 located just downstream of transmembrane (TM) 7 that associates with a number of intracellular proteins (Kuramasu et al., 2006). Additionally, many GPCRs possess a PDZ binding site at the very end of the C-terminal domain, which interacts with the PDZ domain of proteins required for biosynthetic trafficking of the receptor (Thompson and Kanamarlapudi, 2013; Ango et al., 2001).

Agonist-induced GPCR internalisation is predominantly mediated by GPCR kinases (GRKs), arrestins and clathrin coated pits. GRKs phosphorylate agonist-activated GPCRs to facilitate the recruitment of arrestins, which target the GPCRs to clathrin-coated pits for rapid internalisation (Gurevich and Gurevich, 2006). In addition to its role in trafficking of newly synthesised GPCRs, the C-terminal domain can interact with intracellular proteins involved in the internalisation of the receptor (Kuramasu et al., 2006). The tyrosine motif (YXXΦ) within the C-terminus has been shown to associate with clathrin (Bonifacino and Traub, 2003). The β<sub>3</sub>-adrenoceptor (AR) contains a PXXP motif within the C-terminal domain that interacts with Src, which results in the activation of ERK (Cao et al., 2000). Further, an NPXXY motif within TM7 close to the C-terminal domain of the serotonin 5-hydroxytryptamine 2a (5-HT<sub>2a</sub>) receptor interacts with ADP-ribosylation factor 1 (ARF1) small GTPase and couples to phospholipase D (PLD) in a heterotrimeric G-protein-independent manner (Robertson et al., 2003).

A dileucine (LL) motif within the C-terminal domain of some GPCRs has been shown to promote some GPCRs internalisation by binding to adapter proteins (Ferguson, 2001). GPCRs, such as the neurokinin 1, β<sub>2</sub>-AR and the angiotensin II receptor (AT<sub>2</sub>R), require the conserved aromatic residue tyrosine in the C-terminal domain for their internalisation (Bohm et al., 1997b; Thomas et al., 1995; Barak et al., 1994). A mutation of Ser<sup>344</sup> within the C-terminal domain of the δ-opioid receptor (DOR) prevents protein kinase C (PKC) dependent phosphorylation required for internalisation of the receptor (Xiang et al., 2001). The GLP-1R contains three serine doublets at positions Ser<sup>441,442</sup>, Ser<sup>444,445</sup> and Ser<sup>451,452</sup> and their phosphorylation is also important for internalisation of the receptor (Widmann, 1997). Further, phosphorylation of some serine doublets within the C-terminal domain of the GLP-1R is mediated by PKC (Widmann et al., 1996a). Moreover, the mutation of Glu<sup>408</sup>, Val<sup>409</sup>, Gln<sup>410</sup>, which are conserved among family B GPCRs, in the C-terminus of GLP-1R has been shown to affect GLP-1R agonist binding and activity (Vazquez et al., 2005a).

Some GPCRs require E(X)<sub>3</sub>LL, FN(X)<sub>2</sub>LL(X)<sub>3</sub>L, F(X)<sub>3</sub>F(X)<sub>3</sub>F, YXXΦ, PPXXFR, PXXP, NPXXY and LL motifs within the C-terminal domain for biosynthetic trafficking, interactions with intracellular signalling proteins and internalisation of the receptor (Dong et al., 2007). However, these motifs are not present within the C-terminus of GLP-1R. Therefore, the aim of this study was to establish the importance of residues and regions within the C-terminal domain of the human GLP-1R (hGLP-1R) for the receptor biosynthetic trafficking to cell surface, activity and internalisation using a number of C-terminal deletion and site-directed mutants. It was determined that residues 411–418 of the hGLP-1R in the C-terminus are critical in targeting the receptor to the plasma membrane. Residues 419–430 within the C-terminal domain are important for the activity of the receptor (as assessed by cAMP production), most likely for coupling to G<sub>α</sub>s. Further, residues 431–450 within the C-terminus are essential for agonist-induced hGLP-1R internalisation.

## 2. Materials and methods

### 2.1. Materials

The primary antibodies used were rabbit anti-vesicular stomatitis virus glycoprotein (VSVG) (ab34774, Abcam Biochemicals), mouse anti-green fluorescent protein (GFP) (11814460001, Roche), mouse anti-hGLP-1R (MAB2814, R&D Systems), mouse anti-hGLP-1R (sc-390773, Santa Cruz), rabbit anti-phospho ERK1/2 (pERK1/2) (9102, New England Biolabs) and rabbit anti-ERK1/2 (9102, New England Biolabs). The Cy3-conjugated anti-mouse immunoglobulin G (IgG) secondary antibody (715-165-150, Jackson Laboratories) was used for immunofluorescence. The horseradish peroxidase (HRP)-conjugated anti-mouse (NA933) and anti-rabbit (NA934) IgG (GE Healthcare) secondary antibodies were used for immunoblotting. Enhanced chemiluminescence (ECL) select reagent was obtained from GE Healthcare. Liraglutide (GLP-1 analogue) was from Novo Nordisk. All other chemicals were from Sigma unless otherwise stated.

#### 2.1.1. Plasmids

The cDNA of SP-VSVG-hGLP-1RΔN23, containing the signal peptide (SP, 1–23 amino acids) coding sequence followed by VSVG-epitope coding sequence, was cloned into pEGFP-N1 vector (Clontech), as described previously (Thompson and Kanamarlapudi, 2015) for expression as the N-terminus VSVG-tagged (after the SP) and the C-terminus GFP-tagged fusion protein in mammalian cells (SP-VSVG-hGLP-1RΔN23-GFP). The SP-VSVG-hGLP-1RΔN23 with no GFP-tag and its C-terminal deletion constructs were generated by PCR using sequence specific primers containing *EcoRI* restriction site (5' primer), *Sall* restriction site and stop codon (3' primer) and SP-VSVG-hGLP-1RΔN23-GFP plasmid as the template, and cloning into the same sites of pEGFP-N1. The E408A, V409A, Q410A mutation within the hGLP-1R was generated using Quick-change II XL site-directed mutagenesis kit (Stratagene) and SP-VSVG-hGLP-1RΔN23-GFP plasmid as the template (Kanamarlapudi, 2014). The mutants with internal deletions (Δ) within the C-terminus of hGLP-1R were generated using Q5 site directed mutagenesis kit (New England Biolabs) and SP-VSVG-hGLP-1RΔN23-GFP plasmid as the template. The mutations, deletions and right reading frames were confirmed by DNA sequencing of the constructs.

### 2.2. Cell culture and transfection

Human embryonic kidney 293 (HEK293) cells were maintained at 37 °C in a 5% CO<sub>2</sub> humidified environment in Dulbecco's modified Eagle medium (DMEM; serum free medium [SFM]) supplemented with 10% foetal calf serum, 2 mM glutamine, 100 U/ml penicillin

Download English Version:

<https://daneshyari.com/en/article/2195656>

Download Persian Version:

<https://daneshyari.com/article/2195656>

[Daneshyari.com](https://daneshyari.com)